CRISPR/CAS9 untuk Modifikasi Gen E7 pada HPV-6 dan HPV-11 sebagai Tatalaksana Kuratif Condyloma Acuminata
DOI:
https://doi.org/10.46799/jhs.v3i5.495Keywords:
condyloma acuminata;, crispr/cas9;, HPV-6;, HPV-11.Abstract
Sexually Transmitted Diseases (STDs) or Venereal Diseases (VD) are diseases that are transmitted through sexual intercourse, either vaginal, anal, or oral. HPV infection has a large number of about one million cases every day. One study conducted by WHO stated that 31% of women in Indonesia were exposed to infection from this virus. The HPV that can cause Condyloma Acuminata are HPV-6 and HPV-11. Although pharmacological and preventive therapies such as vaccines have been carried out, the number of sufferers is still increasing and becomes a burden for the country because in general this disease attacks the productive age population, so it is time to take a more sophisticated approach to the curative treatment of this disease. Looking for the latest curative methods that can stop condyloma acuminate permanently in each individual. The research method used is by conducting a literature study through several journal databases such as Pubmed, Cinahl, Google Scholar, and others. Based on several studies, it was found that CRISPR/Cas9 proved to be effective in suppressing the expression of the E7 protein and its sequence, proliferation and at the same time inducing apoptosis through the caspase-3 pathway in the conservative genome-specific proteins E7 HPV-6 and HPV-11. Not only decreasing expression and increasing deletion of the target genome, CRISPR/Cas9 has also been shown to be very efficient in suppressing cell proliferation. Keratin cells that have been exposed to the E7 HPV-6 and HPV-11 genomes will cause uncontrolled cell proliferation. With this method, the treatment of Condyloma Acuminata can be carried out effectively and efficiently so that it does not cause recurrence in the sufferer.
Published
Issue
Section
License
Copyright (c) 2022 Asep Wirayasa
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under aCreative Commons Attribution-ShareAlike 4.0 International (CC-BY-SA). that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.